Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma

被引:76
作者
Sun, Matthew Z. [1 ]
Oh, Taemin [2 ]
Ivan, Michael E. [1 ]
Clark, Aaron J. [1 ]
Safaee, Michael [1 ]
Sayegh, Eli T. [2 ]
Kaur, Gurvinder [2 ]
Parsa, Andrew T. [2 ]
Bloch, Orin [2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[2] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
glioblastoma; overall survival; progression-free survival; treatment delay; The Cancer Genome Atlas; oncology; ADJUVANT TEMOZOLOMIDE; WAITING-TIMES; RADIOTHERAPY; DELAY; CONCOMITANT; RADIATION; EORTC;
D O I
10.3171/2014.9.JNS14193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (<= 20 days vs >= 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (>42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [41] Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival
    John, Flora
    Bosnyak, Edit
    Robinette, Natasha L.
    Amit-Yousif, Alit J.
    Barger, Geoffrey R.
    Shah, Keval D.
    Michelhaugh, Sharon K.
    Klinger, Neil V.
    Mittal, Sandeep
    Juhasz, Csaba
    NEURO-ONCOLOGY, 2019, 21 (02) : 264 - 273
  • [42] A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy
    Huang, Jiayi
    Campian, Jian L.
    Gujar, Amit D.
    Tran, David D.
    Lockhart, A. Craig
    DeWees, Todd A.
    Tsien, Christina I.
    Kim, Albert H.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 128 (02) : 259 - 266
  • [43] Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients
    Mistry, Akshitkumar M.
    Jonathan, Sumeeth, V
    Monsour, Meredith A.
    Mobley, Bret C.
    Clark, Stephen W.
    Moots, Paul L.
    NEURO-ONCOLOGY PRACTICE, 2021, 8 (05) : 589 - 600
  • [44] Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
    Grossman, Stuart A.
    Ye, Xiaobu
    Piantadosi, Steven
    Desideri, Serena
    Nabors, Louis B.
    Rosenfeld, Myrna
    Fisher, Joy
    CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2443 - 2449
  • [45] Histologic Findings at the Time of Repeat Resection Predicts Survival in Patients with Glioblastoma
    Melnick, Kaitlyn
    Miller, Patricia
    Carmichael, Ethan
    Wang, Yu
    Tran, David
    Kresak, Jesse Lee
    Ghiaseddin, Ashley
    Rahman, Maryam
    WORLD NEUROSURGERY, 2022, 168 : E451 - E459
  • [46] Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis
    Wang, Chonghao
    Zhu, Na
    Wang, Linshu
    An, Zhe
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C196 - C201
  • [47] Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
    Haj, Amer
    Doenitz, Christian
    Schebesch, Karl-Michael
    Ehrensberger, Denise
    Hau, Peter
    Putnik, Kurt
    Riemenschneider, Markus J.
    Wendl, Christina
    Gerken, Michael
    Pukrop, Tobias
    Brawanski, Alexander
    Proescholdt, Martin A.
    BRAIN SCIENCES, 2018, 8 (01):
  • [48] Utility of Early Postoperative Magnetic Resonance Imaging After Glioblastoma Resection: Implications on Patient Survival
    Mrowczynski, Oliver D.
    Zammar, Samer
    Bourcier, Alexandre J.
    Langan, Sara T.
    Liao, Jason
    Specht, Charles S.
    Rizk, Elias B.
    WORLD NEUROSURGERY, 2018, 120 : E1171 - E1174
  • [49] Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients A single-center analysis
    Roh, Tae Hoon
    Park, Hun Ho
    Kang, Seok-Gu
    Moon, Ju Hyung
    Kim, Eui Hyun
    Hong, Chang-Ki
    Ahn, Sung Soo
    Choi, Hye Jin
    Cho, Jaeho
    Kim, Se Hoon
    Lee, Seung Koo
    Kim, Dong Seok
    Kim, Sun Ho
    Suh, Chang-Ok
    Lee, Kyu Sung
    Chang, Jong Hee
    MEDICINE, 2017, 96 (27)
  • [50] Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma
    Pirzkall, Andrea
    McGue, Colleen
    Saraswathy, Suja
    Cha, Soonmee
    Liu, Raymond
    Vandenberg, Scott
    Lamborn, Kathleen R.
    Berger, Mitchel S.
    Chang, Susan M.
    Nelson, Sarah J.
    NEURO-ONCOLOGY, 2009, 11 (06) : 842 - 852